4,210 results match your criteria Anti-Cancer Drugs[Journal]


Circular RNA circMRPS35 regulates progression and autophagy in osteosarcoma cells by recruiting KAT6B to govern FOXO3.

Anticancer Drugs 2022 Apr 29. Epub 2022 Apr 29.

Department of Biochemistry and Molecular Biology, College of Medicine, Yanbian University, Yanji, China.

Osteosarcoma serves as frequently occurred bone malignancy that displays low survival rate and high incidence of metastasis. Circular RNAs (circRNAs) have been reported as the crucial molecules in osteosarcoma development. However, the effect of circRNA circMRPS35 on osteosarcoma remains unclear. Read More

View Article and Full-Text PDF

Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma.

Anticancer Drugs 2022 Jun;33(5):459-466

Department of Urology, Kochi Medical School, Kochi University, Nankoku, Japan.

The objective was to evaluate the usefulness of sarcopenia and the neutrophil/lymphocyte ratio (NLR) as therapeutic efficacy predictors in patients who received pembrolizumab after platinum-based chemotherapy for advanced urothelial carcinoma (aUC). Forty-four patients with aUC were enrolled. Patients' background characteristics and clinical factors, the skeletal muscle index, and the psoas muscle index were evaluated. Read More

View Article and Full-Text PDF

Circ_0009035 regulates the progression of cervical cancer by targeting miR-1305/CREBRF axis.

Anticancer Drugs 2022 Jul 5;33(6):539-552. Epub 2022 Apr 5.

Department of Obstetrics and Gynecology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou City, Zhejiang Province, China.

Circular RNAs (circRNAs) have a crucial role in the occurrence of many diseases, such as tumors. Yet the roles of circ_0009035 (circRACGAP1) in cervical cancer are not fully characterized. The expression levels of circRACGAP1, miR-1305 and cAMP-responsive element-binding protein 3 regulatory factor (CREBRF) were detected by using real-time quantitative PCR or western blot. Read More

View Article and Full-Text PDF

Ubiquitin-specific protease 1 inhibition sensitizes hepatocellular carcinoma cells to doxorubicin by ubiquitinated proliferating cell nuclear antigen-mediated attenuation of stemness.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Clinical Laboratory, Women and Children's Health Care Center of Hainan Province Department of Radiation Oncology, Hainan Cancer Hospital, Haikou, P.R. China Department ofMedical Oncology, Hainan Cancer Hospital, Haikou, P.R. China.

Currently, resistance to the chemotherapeutic agent doxorubicin (Dox) in hepatocellular carcinoma (HCC) cells is an obstacle in developing effective Dox-targeted clinical therapies. Ubiquitin-specific protease 1 (USP1) plays a crucial role in the progression of multiple cancers. In this study, the purpose was to investigate the effect of USP1 depletion with chemotherapeutant Dox on the HCC cells. Read More

View Article and Full-Text PDF

Circ_0058063 promotes progression of thyroid cancer by sponging miR-330-3p/SDC4 axis.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Endocrinology and Metabolism and Department of Rehabilitation Medicine, Clinical Medical College of Chengdu Medical College, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.

Circular RNA takes a crucial part in carcinogenesis. Circ_0058063 has been found to act as an oncogene in esophageal cancer and bladder cancer, but its role in thyroid cancer (TC) is still under investigation. Therefore, we carried out a study to understand its role in TC and its association with miR-330-3p. Read More

View Article and Full-Text PDF

Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Thoracic Medical Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Selpercatinib has been approved by most major regulatory bodies in 2020 and become the standard therapy for rearranged during transfection (RET)-rearranged nonsmall-cell lung cancer (NSCLC). Knowledge is limited regarding mechanisms of resistance to selpercatinib and effective treatment. One study identified MNNG HOS transforming (MET) amplification as intrinsic or secondary resistance mechanism from four patients, and three of them showed ~40% tumor reduction when treated with selpercatinib plus crizotinib. Read More

View Article and Full-Text PDF

Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Experimental, Diagnostic and Specialty Medicine, Policlinico di Sant'Orsola University Hospital Division of Medical Oncology, Department of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

In recent years, immune checkpoint inhibitors (ICIs), including nivolumab and pembrolizumab have revolutionized the treatment landscape in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, many patients do not respond to ICIs for reasons that remain largely unknown. For patients who progress on ICIs, chemotherapy and/or biologic therapies are the most widely used treatments based on the clinician's choice, with no defined sequence strategy. Read More

View Article and Full-Text PDF

Mitochondrial protein LETM1 and its-mediated CTMP are potential therapeutic targets for endometrial cancer.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Obstetrics and Gynecology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan Department of Obstetrics and Gynecology Department of Stomatology, Shengli Oilfield Central Hospital, Dongying, China.

Leucine zipper/EF hand-containing transmembrane-1 (LETM1) is an important mitochondrial protein, while its function in endometrial cancer remains unknown. This study aimed to explore the function of LETM1 in endometrial cancer and reveal the underlying mechanisms involving carboxy-terminal modulator protein (CTMP). Immunohistochemistry was performed to detect the expression of LETM1 and CTMP in normal, atypical hyperplastic and endometrial cancer endometrial tissues. Read More

View Article and Full-Text PDF

Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Respiratory and Critical Care Medicine, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical School of Jinan University, Shenzhen Municipal Institute of Respiratory Medicine, Shenzhen, Guangdong, China.

Treatment options for heavily treated anaplastic lymphona kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) patients, who typically bear-resistant mechanisms to ALK tyrosine kinase inhibitors (TKIs), are usually limited to chemotherapy, which elicits limited clinical benefit and may incur severe toxicity. It is clinically relevant to explore other revenues for these patients. poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 (BRCA1/2)-mutated patients in a few tumor types. Read More

View Article and Full-Text PDF

Dexmedetomidine disrupts esophagus cancer tumorigenesis by modulating circ_0003340/miR-198/HMGA2 axis.

Anticancer Drugs 2022 06;33(5):448-458

Department of Anesthesia, The Fourth People's Hospital of Jinan (The Third Affiliated Hospital of Shandong First Medical University), Jinan, China.

More and more studies have focused on the regulatory role of circular RNAs (circRNAs) in various cancers. However, it is not clear how dexmedetomidine (DEX) affects esophagus cancer progression by affecting the expression of circRNAs. This study aimed to investigate the role of DEX in esophagus cancer and its underlying mechanism. Read More

View Article and Full-Text PDF

MicroRNA hsa-miR-657 promotes retinoblastoma malignancy by inhibiting peroxisome proliferator-activated receptor alpha expression.

Anticancer Drugs 2022 06;33(5):478-488

Department of Ophthalmology, Wuchang Eyegood Ophthalmic Hospital, Wuhan, China.

Retinoblastoma is a familial inherited embryonic neuroretinal malignancy with a low survival rate and poor prognosis. Our study aimed to evaluate the potential interaction between microRNA miR-657 and the peroxisome proliferator-activated receptor alpha (PPARA) in retinoblastoma. Expression of miR-657 and PPARA was analyzed in retinoblastoma tissues and cells using RT-qPCR. Read More

View Article and Full-Text PDF

LncRNA BBOX1-AS1 promotes pituitary adenoma progression via sponging miR-361-3p/E2F1 axis.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Department of Neurosurgery, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.

Pituitary adenoma is one of the most common intracranial tumors, more and more studies have shown that long non-coding RNA (lncRNA) plays a very important role in pituitary adenoma. However, there are few reports on the function of lncRNA BBOX1-AS1 in pituitary adenomas, and further exploration is needed. The objective of this research is to figure out what function BBOX1-AS1 plays in pituitary adenoma and how it regulates it. Read More

View Article and Full-Text PDF

In-silico drug-likeness analysis, ADME properties, and molecular docking studies of cyanidin-3-arabinoside, pelargonidin-3-glucoside, and peonidin-3-arabinoside as natural anticancer compounds against acting receptor-like kinase 5 receptor.

Anticancer Drugs 2022 Jul 23;33(6):517-522. Epub 2022 Mar 23.

Department of Translational Oncology, Institute of Oncology, Dokuz Eylul University, İzmir, Turkey.

Background: The aim of the study was in-silico drug-likeness analysis, absorption, distribution, metabolism, and excretion (ADME) properties, and molecular docking studies of anthocyanins as natural anticancer compounds against acting receptor-like kinase 5 (ALK5) receptor. Transforming growth factor-β (TGF-β) plays an essential role in various cellular processes. Increased expression of TGF-β and its receptor TGFβR-I (i. Read More

View Article and Full-Text PDF

TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA.

Anticancer Drugs 2022 06;33(5):489-501

Laboratory Medicine Center, The First School of Clinical Medicine, Southern Medical University.

A hypoxic tumor microenvironment (TME) promotes cancer progression, yet its value as a therapeutic target remains underexploited. Tripartite motif-containing 72 (TRIM72) may protect cells against various stresses including hypoxia. Recently, low TRIM72 expression has been implicated in cancer progression. Read More

View Article and Full-Text PDF

Hypoxia-inducible factor-1α inhibition augments efficacy of programmed cell death 1 antibody in murine prostatic cancer models.

Anticancer Drugs 2022 Jul 23;33(6):587-594. Epub 2022 Mar 23.

Department of Urology, Tangshan Gongren Hospital, Tangshan, China.

This study was designed to explore whether hypoxia-inducible factor-1α (HIF-1α) inhibitor could enhance immunotherapy efficacy in prostate cancer. Western blot was used to detect the expression of HIF-1α in the tumor and peritumor tissues from prostate cancer patients. The analysis from Cancer Genome Atlas database was used to show an association between HIF-1α expression and survival rate in prostate cancer patients. Read More

View Article and Full-Text PDF

The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Surgery Department of Pathology Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden Oncode Institute, The Netherlands.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer, mainly due to its delayed diagnosis and lack of effective therapeutic options. Therefore, it is imperative to find novel treatment options for PDAC. Here, we tested a series of conventional chemotherapeutics together with anthracycline compounds as single agents or in combination, determining their effectivity against established commercial and patient-derived, low-passage PDAC cell lines. Read More

View Article and Full-Text PDF

The marine factor 3,5-dihydroxy-4-methoxybenzyl alcohol suppresses growth, migration and invasion and stimulates death of metastatic human prostate cancer cells: targeting diverse signaling processes.

Anticancer Drugs 2022 06;33(5):424-436

Department of Research and development, Watanabe Oyster Laboratory Co. Ltd., Hachioji, Tokyo, Japan.

Prostate cancer is metastatic cancer and is the second leading cause of cancer-related death in men. It is needed to develop more effective treatment for metastatic prostate cancer. The present study investigates whether the novel factor 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA), which was isolated from marine oyster, suppresses the activity of metastatic human prostate cancer PC-3 or DU-145 cells. Read More

View Article and Full-Text PDF

Oncolytic viral therapy engenders a clinical response in a recurrent ovarian cancer patient.

Anticancer Drugs 2022 06;33(5):513-516

The Women's Cancer Research Foundation, Newport Beach.

Platinum-resistant ovarian cancer frequently develops in response to multiple lines of chemotherapy, whereupon the disease becomes relatively intractable and clinical recourse is limited. We document a 58-year-old, advanced-stage, platinum-resistant ovarian cancer patient who previously failed numerous cytotoxic and targeted therapy regimens. She was referred to our gynecologic oncology service with a California (CA)-125 of 3194 U/mL and underwent a modified vaccinia virus coinciding with an Institutional Review Board-approved clinical trial. Read More

View Article and Full-Text PDF

RNF185 antisense RNA 1 (RNF185-AS1) promotes proliferation, migration, and invasion in papillary thyroid carcinoma.

Anticancer Drugs 2022 Jul 23;33(6):595-606. Epub 2022 Mar 23.

Nuclear Medicine and Radiotherapy, Central Hospital of Zibo, Zibo, China.

Long noncoding RNA (lncRNA) plays an important role in multiple cancers. So far, the exact function of lncRNAs in papillary thyroid carcinoma (PTC) is unclear. The purposes of this work were to investigate the function and underlying mechanisms of RNF185 antisense RNA 1 (RNF185-AS1) in PTC. Read More

View Article and Full-Text PDF

CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.

Anticancer Drugs 2022 06;33(5):437-447

Department of Pulmonary and Critical Care Medicine, Zigong first people's Hospital, Zigong, China.

Background: Circular RNAs (circRNAs) serve a key role in lots of cancers. The outcomes of upregulated circular RNA forkhead box K2 (circFOXK2) on non-small cell lung cancer (NSCLC) persisted uncertainly. In this study, the role of circFOXK2 in NSCLC was inspected. Read More

View Article and Full-Text PDF

LncRNA SNHG11 enhances bevacizumab resistance in colorectal cancer by mediating miR-1207-5p/ABCC1 axis.

Anticancer Drugs 2022 Jul 23;33(6):575-586. Epub 2022 Mar 23.

Cancer Center, Huizhou First Hospital, Huizhou.

Long noncoding RNAs (lncRNAs) have been reported to serve as vital regulators in the chemoresistance of human cancers, including colorectal cancer (CRC). In this study, we aimed to explore the functions of lncRNA small nucleolar RNA host gene 11 (SNHG11) in the resistance of CRC to bevacizumab. Quantitative real-time PCR, western blot assay or immunohistochemistry assay were performed to examine the expression of SNHG11, microRNA-1207-5p (miR-1207-5p), ATP binding cassette subfamily C member 1 (ABCC1) and Ki67. Read More

View Article and Full-Text PDF

Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report.

Anticancer Drugs 2022 06;33(5):509-512

Department of Comprehensive Cancer Treatment, Weihai Municipal Hospital, Weihai.

Contrary to the success of antihuman epidermal growth factor receptor 2 (HER2) therapy in HER2-amplified breast cancer, the optimal targeted drug therapy for HER2-amplified lung cancer remains to be determined clinically. In this report, a nonsmoker, Chinese, old, male patient was diagnosed with cT2bN3M0 nonsmall cell lung cancer with genetic testing revealing HER2 amplification. Though the patient received successful microwave ablation, the results of reexamination after two cycles of afatinib monotherapy showed disease progression. Read More

View Article and Full-Text PDF

Advanced thymic lymphoepithelioma-like carcinoma with bone marrow metastases treated by immunotherapy combined with antiangiogenesis therapy: a case report.

Anticancer Drugs 2022 Mar 23. Epub 2022 Mar 23.

Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Thymic lymphoepithelioma-like carcinoma (LELC) is a rare primary malignant neoplasm originating from the thymus. Thymic LELC diagnosis is often terminal when diagnosed, some patients have lost the opportunity for surgery. Platinum- and anthracycline-based systemic chemotherapy are the first-line treatment plan; however, there is no clear consensus on therapy when first-line treatment fails because of the lack of cases of advanced thymic LELC. Read More

View Article and Full-Text PDF

Circ_0003146 upregulates SCARB1 expression by acting as a miR-1272 sponge to promote malignant behaviors of clear cell renal cell carcinoma.

Anticancer Drugs 2022 Jul 8;33(6):564-574. Epub 2022 Mar 8.

Departments of Urology.

Circular RNAs (circRNAs) exhibit essential regulation in the malignant development of clear cell renal cell carcinoma (ccRCC). The aims of this study were to investigate the role and mechanism of circ_0003146 in the biologic behaviors of ccRCC. RNA level analysis was performed through reverse transcription-quantitative PCR assay. Read More

View Article and Full-Text PDF

LncRNA HLA-F-AS1 attenuates the ovarian cancer development by targeting miR-21-3p/PEG3 axis.

Anticancer Drugs 2022 Mar 8. Epub 2022 Mar 8.

Department of Gynecology and Obstetrics, Wuhan No.6 Hospital, Affiliated Hospital of Jianghan University, Wuhan, Hubei, China.

Dysregulated long noncoding RNA (lncRNA) HLA-F-AS1 is depicted in numerous cancers. However, its function in ovarian cancer has yet to be clarified. LncRNA HLA-F-AS1, miR-21-3p, and PEG3 expressions in ovarian cancer tissues and cells were measured via reverse transcription quantitative PCR. Read More

View Article and Full-Text PDF

Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p/6-phosphofructo-2-kinase/fructose-2,6-bisphosphataseisotype 3 axis.

Anticancer Drugs 2022 Jul 8;33(6):553-563. Epub 2022 Mar 8.

Department of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.

Colorectal cancer (CRC) is one of the most fatal cancers in the world. Circular RNA sterile alpha motif domain containing 4A (circSAMD4A) was found to be highly expressed in CRC and promoted the tumorigenesis of CRC. However, the role of circSAMD4A in 5-fluorouracil (5-Fu) resistance of CRC is yet to be clarified. Read More

View Article and Full-Text PDF

Inhibiting nonhomologous end-joining repair would promote the antitumor activity of gemcitabine in nonsmall cell lung cancer cell lines.

Anticancer Drugs 2022 06;33(5):502-508

Department of Thoracic Surgery, The Fourth Medical Center of Chinese PLA General Hospital, Beijing.

Nonsmall cell lung cancer (NSCLC) is a major type of lung cancer. In current study, we aim to evaluate whether the combination of Ku70/80 heterodimer protein inhibitor STL127705 and gemcitabine would be more favorable approach for the treatment of NSCLC compared with monotreatment with gemcitabine. Clongenic survival assay was used to determine the survival and sensitivity to irradiation. Read More

View Article and Full-Text PDF

Mechanisms of GZ17-6.02 resistance.

Anticancer Drugs 2022 06;33(5):415-423

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.

Objectives: The drug GZ17-6.02 is undergoing phase I in solid tumor patients (NCT03775525). The present studies initially determined the impact of prolonged exposure of colorectal tumors to GZ17-6. Read More

View Article and Full-Text PDF

LncRNA ZFPM2-AS1 drives the progression of nasopharyngeal carcinoma via modulating the downstream miR-3612/DTL signaling.

Anticancer Drugs 2022 Jul 8;33(6):523-533. Epub 2022 Mar 8.

Department of Otolaryngology, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, Hubei, China.

LncRNA ZFPM2-AS1 has been illuminated to function as a carcinogenic driver in various human cancers. Whereas, the role of ZFPM2-AS1 in nasopharyngeal carcinoma (NPC) remains puzzled. To further understand NPC pathogenesis, we investigated the regulatory effects of ZFPM2-AS1 in NPC. Read More

View Article and Full-Text PDF

Outcome of primary androgen deprivation therapy in super-elderly men with localized high-risk prostate cancer.

Anticancer Drugs 2022 Jul 8;33(6):534-538. Epub 2022 Mar 8.

Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.

The purpose of this study is to provide certain data on clinical outcome of primary androgen deprivation therapy in men over 80 years of age with localized high-risk prostate cancer. This study included 54 Japanese super-elderly men with high-risk prostate cancer treated with primary androgen deprivation therapy between 2005 and 2015. The median overall survival was 9. Read More

View Article and Full-Text PDF